Joe may have been saying, as you state, that Altucell "has

New Post Public Reply Private Reply Replies (1) Message Board
Buildit Msowid #11769
310
Joe may have been saying, as you state, that Altucell "has the right to go their separate ways if and only if...". Or, as he stated it, "Wrong as usual if you took the time to read it's from when any Govt interaction or delay occurs till that delay is over".

However, the 8-k states:

"If ALTuCELL chooses to cancel the transaction as a result of delays due to forces beyond the control of Generex, including government regulatory delays or extended reviews by regulators that delay approvals of corporate actions... ALTuCELL agrees to return all payments made by Generex."

That is clear as day. They can choose to walk after 30 days if they want, at the sole pain of returning the deposit and operations funding GNBT has given them to that point.

Now, they may INTEND to extend the deal if necessary. But I doubt any legal team would back Joe's implication that the 30 day clock doesn't start ticking until the gov't review are over, at least as far as the 8-k shows us.

And that's the real crux of my point. Yes, Olaregen and others have continued to extend their deals, to-date. And that has been a life saver for GNBT (and us), IMHO. However, everyone has their limits. What would happen if Olaregen decided to walk? Would others follow? We won't know until it happens. But if it happens, it could be disastrous.

Joe has assembled a fine looking ship. But right now, the parts of the ship are held together by rope. Once the div is in the rear view mirror, the S-1 is approved, NGIO spins (pushing up the share price), S-1 funding is received, and Joe pays off the deals and sets the machine to work, the ship will be welded together, and we will be able to get it up to speed.

We know that Joe has a LOT of info in his head that we are not privy to. Maybe he mistakenly bases some of these comments on that type of info. For example, maybe Altucell TOLD JOE that they would not really start the clock until 30 days after the gov't review period is up (or that they intend to keep extending to that point), because they really want to be part of Joe's team. So that could be what Joe thinks when he reads a post like Hylander's. However, public info sometimes is contrary to what Joe insinuates (based on his deeper level of knowledge) when he comes to the boards and lets loose on people.

As I have told Joe here and through PM, he needs to remember that he is stuck with us retail investors until he can get GNBT onto the NAZ. We are not professionals, and this is not our full time job. We make mistakes, we miss things, we forget details from time to time, but we do the best we can to process and keep up with a fluid and complex situation.

In the meantime, it would behoove Joe, again in my opinion, to treat his shareholders with as much respect on the boards as he does on the calls. That means no drive-by heated comments based on a small sampling of posts. He should either participate by understanding whole conversations, respond professionally to comments, and wait around for people to get back to him or not come here at all... especially when he appears to be incorrect, as is the case here, unless he can point to another document.

To that point, I'm still hoping Joe comes back to explain his comment to Hylander and what info he can share with us that backs up his claim...

==============
I did read the 8k, several times. and of course i read your pointing out Joe's explanation, discrepancy wise. And i did go back and reread the 8k. What Joe was referring to, according to my understanding, was Altucel has the right to go their separate ways if and only if (regulatory denials and or a long process, natural disasters and other unforeseen events) the reasons listed hereto. The way i understood it and Joe's explanation, is that they can not cancel because of other reasons and do welcome more extensions, if necessary, to continue with this venture......hence why Joe was so upset (11691)....

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lawyers Juggle AI's Promise and Perils in 2026

Updated Category News Views 104

AI's Growing Pains in the Legal Arena Looks like the legal eagles are getting a run for their money with AI entering the courtroom. Bloomberg Law's 2026 AI in Practice report dives deep into this legal labyrinth. You got attorneys leaning on AI to keep the gears turning, but they're also clutching their pearls over potential pitfalls. Trust Issues: Humans vs. Machines The...

Continue Reading
Siemens Set to Acquire Lauterbach in Strategic Move

Updated Category News Views 81

Siemens Seizing New Opportunities with Lauterbach Acquisition Bam! Siemens is on the move, folks, snapping up Lauterbach to bolster its semiconductor design arsenal. Now, if you’ve got your eyes glued to innovation in chip design, like yours truly, then strap in because this merger is more than just a footnote on some dusty tech page. It's a game-changer when it comes...

Continue Reading
Jinko Solar Joins B20 Summit: Energy Forefront Focus

Updated Category News Views 145

Jinko Solar's Invitation to the B20 Summit Never a dull moment in the solar space, especially when Jinko Solar, a big shot in clean energy, jumps into the spotlight at the B20 Summit in the U.S. Awash with high-profile discussions, Jinko's not just chatting—it's the only photovoltaic firm strutting its stuff in D.C. with gutsy calls for energy reform. Key Takeaways from...

Continue Reading
Paulex Bio's Grant Fuels Bold Diabetes Research Push

Updated Category News Views 89

Cracking the Diabetes Code: A New Hope Emerging It ain't every day you hear about a biotech outfit snagging an NIH Fast-Track grant with the potential to upend diabetes treatment, but Paulex Bio's recent score turns heads. Their brainchild, PAL-119, promises to tackle diabetes not by slapping a band-aid on symptoms, but by getting to the rotten core of the disease: the...

Continue Reading
Shukla MD's New Concierge Program Boosts Patient Care

Updated Category News Views 63

Shifting the Healthcare Paradigm Imagine a healthcare world where doctors actually have the time to listen and engage with you beyond just scribbling notes in haste. That's what's brewing over in Westchester, where Dr. Rachana and Dr. Vaishalee Shukla are putting the old-school patient-doctor relationship front and center with their Hybrid Choice concierge program. Run...

Continue Reading
NHTSA, Ad Council Unveil New Anti-Buzzed Driving PSAs

Updated Category News Views 71

Taking Aim at a Deadly Habit Everyone's got that gut feeling when a day-long meeting runs over or you're stuck in traffic — impatience morphed with slow burn menace. Now picture a whole campaign gunning for that vibe but in the hands of the young folks, those from 21 to 34. That's what we're talking about here, with the Ad Council and NHTSA serving up some fresh public...

Continue Reading
Cognizant Boosts Claude AI with 25,000 Pro Workforce

Updated Category News Views 157

Moving AI from Theory to Practice You know, AI isn't about just keeping up with the hype; it's about shoving those algorithms right where they can do the most good—right at the core of business operations. And that’s precisely what Cognizant's cooking up with their fresh-off-the-press Claude Frontier Capability Group. They’ve thrown more than 25,000 pros into the...

Continue Reading
Bandwidth's SI Innovations: A New Dawn or Just Hype?

Updated Category News Views 56

Bandwidth Unleashes Super Intelligence at Reverb Right off the bat, Bandwidth's Reverb showcase was enough to stir up some excitement in the air. The company laid out a feast of technological advancements with their Super Intelligence (SI) innovations that claim to redefine how enterprises communicate. But here's the rub—while these developments sound thrilling, the...

Continue Reading
Parachute Health Urges HME Transformation Through Collaboration

Updated Category News Views 159

The Road to Digital Unity in HME Cranking through the gears of the healthcare industry is no mean feat, but Parachute Health seems ready to throw some fresh oil on the machine. In a landscape riddled with complexities, they're sounding the call for a more unified digital infrastructure in the Home Medical Equipment (HME) sector through their latest white paper. We're...

Continue Reading
What's at Stake: Pearl Diver's Q3 2026 Earnings Call

Updated Category News Views 60

Upcoming Unveiling: Pearl Diver's Latest Financials Heads up, folks. November 16 can't come soon enough for those keeping tabs on Pearl Diver Credit Company Inc. (NYSE: PDCC, PDPA). The bigwigs over there are planning to spill the beans on their third quarter 2026 financial results. They'll kick things off before the market even has its first cup of java on Monday morning...

Continue Reading

Top 5 Most Recently Viewed Articles

Boardwalktech Software to Showcase Innovations at Upcoming Event

Updated Category News Views 161

Boardwalktech Software Demonstrates Commitment to Innovation Boardwalktech Software Corp. (TSXV: BWLK) (OTCQB: BWLKF), recognized as a leader in the Intelligent Information Platform sector, has announced that their CEO and Chairman, Andrew Duncan, is set to present at the highly anticipated Planet MicroCap Showcase. This event, in partnership with MicroCapClub, serves as...

Continue Reading
Sabio Holdings' Creator Television® Earns Top Newcomer Award

Updated Category News Views 136

Sabio Holdings' Creator Television® Triumphs at Industry Awards In an impressive early success, Creator Television®, a project of Sabio Holdings, has clinched the 'Most Significant Newcomer' award at the InteractiveTV Today (ITVT) Awards. This recognition comes as a significant milestone for the company during Creator TV's first six months since launch. An Award for...

Continue Reading
Starbucks Corporation Under Investigation by Kahn Swick & Foti

Updated Category News Views 344

Starbucks Corporation Faces Investigation In recent developments, Kahn Swick & Foti, LLC has started an investigation regarding Starbucks Corporation (NASDAQ: SBUX). Led by former Louisiana Attorney General Charles C. Foti, Jr., this inquiry raises important questions about the company and its executives. Financial Performance Raises Red Flags Starbucks' recent financial...

Continue Reading
Innovative Nitric Oxide Therapy Shows Promise in Cancer Treatment

Updated Category News Views 213

Exploring the Efficacy of LV UNO Therapy in Cancer Treatment Beyond Cancer, Ltd. has introduced groundbreaking preclinical data showcasing the benefits of Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) therapy. This therapy, when combined with immune checkpoint inhibitors, demonstrates significant potential for enhancing patient outcomes in cancer treatments....

Continue Reading
Wabash Partners with Decisiv to Enhance Service Management

Updated Category News Views 305

Wabash and Decisiv Forge a New Partnership Wabash, a leading provider of innovative supply chain solutions, has formed a strategic partnership with Decisiv to enhance service management capabilities within its dealer network. This collaboration aims to streamline service event management and improve uptime for Wabash customers. Decisiv's Impact on Service Management The...

Continue Reading